The expanded authorization means that the vaccine, administered through drops in the nose, can be obtained in almost all adults in India. People who have never been vaccinated against COVID-19 are eligible, as well as those who have already been vaccinated against COVID-19. -19 vaccines. An estimated 900 million more people in India have already received two doses of a COVID-19 vaccine.
“We are excited about the authorization of the nasal booster vaccine, which allows this intranasal vaccine to be used in many other people and decrease transmission,” said Michael S. Diamond, M. D. , Ph. D. , Herbert S. Gasser Professor of Medicine and Professor of Molecular Microbiology and Pathology and Immunology. Diamond co-developed the vaccine.
The greatest merit of the nasal vaccine, besides not requiring a needle, is that it triggers an immune reaction in the nose and upper respiratory tract, where the virus enters the body. By doing so, you have the possibility to block the infection and break the transmission cycle. The generation of this nasal vaccine is also adaptable, so the vaccine can be changed temporarily and seamlessly to accommodate emerging variants of interest.
“Many other people don’t seem to be involved in the pandemic, but the virus is still here and other people will still want to get vaccinated for the foreseeable future,” David T said. Curiel, M. D. , Ph. D. , the distinguished professor of radiation oncology, who worked with Diamond to expand the vaccine. “. Going forward, vaccination methods involving a number of other types of vaccines, targeting the same virus, can help us better prepare for the next pandemic. “
Diamond and Curiel, along with members of their labs, created the nasal vaccine at the University of Washington in the early months of the COVID-19 pandemic. In the summer of 2020, the University of Washington legalized the rights to develop, manufacture and commercialize the generation in India to Bharat Biotech International Limited, a leader in vaccine innovation and developer of vaccines against infectious diseases. Last October, the university also legalized generation to Ocugen Inc. , a U. S. -based biogeneration company. vaccines and gene and mobile treatments, for progression in the U. S. USA, Europe and Japan.
Please indicate the appropriate maximum category to facilitate the processing of your request
Thank you for taking the time to provide feedback to editors.
Your opinion is for us. However, we do not guarantee individual responses due to the large volume of messages.